NutraNomics receives first purchase to the new weight loss line item

Draper, UT - (Marketwire Wired - August 27, 2014) - NutraNomics ( OTCBB : NNRX) would be to obtain a first order announce August formulated a total of $ 233,000 for a new line of weight loss products from Dr. Tracy Gibbs, founder of NutraNomics spring 2014 order was approved by a large company in Utah Multi level marketing based , and the company is expected to announce its own brand in September, the introduction of this line. NutraNomics retain exclusive manufacturing rights for the product range and NutraNomics expect to be able to create and offer many other products of your company in the future.

"The quick response time between the development and the distribution of this product line is the ability that Dr. Gibbs and the rest of our team here at NutraNomics" said Mike Brousseau, CEO NutraNomics. "We coordinate the formulation, supply of raw materials and the production of this line within three months, with our experience."

Management believes that this new relationship will not only increase revenue, but also improve the profitability of NutraNomics. "As our new customers in many countries around the world, we expect the new relationship to our presence in the EU and Latin America, where we raise only a small number of customers," Brousseau said.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" that involve statements that are not purely historical observe or beliefs, plans, expectations or intentions are include. Actual results may differ from those in the forward-looking statements presented by many factors, including the uncertainties associated with the development and marketing of new products operates as a development stage development company, competition and market conditions. These forward-looking statements are as of the date hereof, and we have no obligation to update statements where it is not legally required. Although we believe that the beliefs, plans, expectations or intentions contained herein are reasonable, no assurance that they will prove to be accurate. Investors should consult all available information and the factor risk disclosure in our filings with the SEC at www.sec.gov.

These statements have not been evaluated by the Food and Drug Administration. The company's products are not intended to diagnose, treat, cure or prevent any disease.